In Brief: In vivo radiopharmaceuticals
This article was originally published in The Gray Sheet
In vivo radiopharmaceuticals: FDA will hold a public meeting Feb. 27 on developing regulations on the use of in vivo radiopharmaceuticals diagnosis and monitoring. The agency will be soliciting input from patient advocacy groups, physicians, industry and the public concerning the development of new regulations for the review of radiopharmaceutical applications as required by the FDA Modernization Act. Written comments are due March 4. The meeting will begin at 8:00 a.m. in Conference Rooms D and E of FDA's Parklawn building in Rockville, Maryland...
You may also be interested in...
With a proposed IPO, Gland Pharma’s parent company, Fosun Pharma, hopes to raise funds for its injectables business and possibly its COVID-19 vaccine. The move will also cut Chinese ownership against a backdrop of shaky relations between India and China. As investors warm up to pharma stocks, the timing seems right.
In a significant development, China proposes to strengthen the protection of new drugs through not only patent linkage but also patent compensation in the latest draft of its revised Patent Law.
Hedge fund Davidson Kempner is recommending that Qiagen NV renegotiate its planned takeover deal with Thermo Fisher Scientific, arguing that demand for diagnostic fueled by the COVID-19 pandemic makes Qiagen worth more than the price agreed on in March. See what Davidson Kempner’s partner Michael Herzog said about it here.